GoodRx Holdings, Inc. (NASDAQ:GDRX) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of GoodRx Holdings, Inc. (NASDAQ:GDRX) have been given a consensus rating of “Moderate Buy” by the fifteen brokerages that are presently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, four have given a hold recommendation, nine have issued a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $8.86.

A number of equities research analysts recently weighed in on the company. Barclays dropped their price target on GoodRx from $10.00 to $6.00 and set an “overweight” rating for the company in a report on Monday, November 11th. Raymond James upgraded shares of GoodRx from an “outperform” rating to a “strong-buy” rating and set a $10.00 price target on the stock in a research report on Friday, August 9th. Royal Bank of Canada restated an “outperform” rating and issued a $10.00 price objective on shares of GoodRx in a research report on Friday, August 16th. UBS Group reduced their target price on shares of GoodRx from $9.00 to $8.50 and set a “neutral” rating on the stock in a research report on Friday, August 9th. Finally, Citigroup lowered their price target on shares of GoodRx from $10.00 to $7.00 and set a “buy” rating for the company in a report on Wednesday, November 13th.

GoodRx Stock Performance

NASDAQ GDRX opened at $4.76 on Wednesday. The firm has a market cap of $1.81 billion, a price-to-earnings ratio of -158.67, a PEG ratio of 3.57 and a beta of 1.39. The company has a current ratio of 5.48, a quick ratio of 5.48 and a debt-to-equity ratio of 0.70. GoodRx has a 1-year low of $4.09 and a 1-year high of $9.26. The company has a 50 day moving average of $6.11 and a 200-day moving average of $7.29.

Insider Transactions at GoodRx

In related news, major shareholder Equity Vii L.P. Spectrum sold 10,677 shares of the stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $7.86, for a total transaction of $83,921.22. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 4.17% of the stock is owned by insiders.

Hedge Funds Weigh In On GoodRx

A number of large investors have recently bought and sold shares of GDRX. American Century Companies Inc. acquired a new stake in shares of GoodRx in the second quarter valued at approximately $18,183,000. Point72 Asset Management L.P. bought a new position in GoodRx in the third quarter valued at $11,295,000. Rubric Capital Management LP increased its stake in GoodRx by 76.5% in the 2nd quarter. Rubric Capital Management LP now owns 3,736,802 shares of the company’s stock valued at $29,147,000 after buying an additional 1,619,748 shares during the last quarter. Millennium Management LLC lifted its position in GoodRx by 36.5% during the 2nd quarter. Millennium Management LLC now owns 4,121,939 shares of the company’s stock worth $32,151,000 after buying an additional 1,102,758 shares in the last quarter. Finally, Pier Capital LLC acquired a new position in shares of GoodRx during the 3rd quarter worth about $3,259,000. Institutional investors and hedge funds own 63.77% of the company’s stock.

About GoodRx

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.